Compare HNRG & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HNRG | MGTX |
|---|---|---|
| Founded | 1949 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 846.5M | 909.1M |
| IPO Year | 1995 | 2018 |
| Metric | HNRG | MGTX |
|---|---|---|
| Price | $19.26 | $10.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $25.38 | $24.57 |
| AVG Volume (30 Days) | ★ 991.2K | 617.7K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 116.78 | 33.02 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $469,466,000.00 | $81,391,000.00 |
| Revenue This Year | N/A | $141.38 |
| Revenue Next Year | $12.12 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 16.09 | ★ 144.57 |
| 52 Week Low | $14.68 | $5.14 |
| 52 Week High | $24.70 | $11.85 |
| Indicator | HNRG | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 58.64 | 64.46 |
| Support Level | $18.89 | $7.11 |
| Resistance Level | $20.80 | $11.85 |
| Average True Range (ATR) | 0.94 | 0.43 |
| MACD | 0.06 | 0.05 |
| Stochastic Oscillator | 68.68 | 97.71 |
Hallador Energy Co is a vertically integrated, independent power producer (IPP) and fuel company with operations in Indiana. The Company operates across multiple stages of the energy value chain, from accredited capacity and energy to coal. The Company's electric operations are located within the Midcontinent Independent System Operator's (MISO) footprint. The company's business is organized based on the services and products it provide in two segments: (i) Electric Operations and (ii) Coal Operations.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.